These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34857033)

  • 1. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients.
    Leiro B; Phillips D; Duiker M; Harmatz P; Charles S
    Orphanet J Rare Dis; 2021 Dec; 16(1):500. PubMed ID: 34857033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy.
    Garcia P; Phillips D; Johnson J; Martin K; Randolph LM; Rosenfeld H; Harmatz P
    Mol Genet Metab; 2021 May; 133(1):100-108. PubMed ID: 33775523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
    Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
    Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
    Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
    Orphanet J Rare Dis; 2019 May; 14(1):118. PubMed ID: 31142378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ; Atallah ÁN; da Silva EM
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD009806. PubMed ID: 34533215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series.
    İnci A; Okur İ; Tümer L; Biberoğlu G; Öktem M; Ezgü F
    Orphanet J Rare Dis; 2021 Oct; 16(1):438. PubMed ID: 34666789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
    Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
    Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ; Atallah ÁN; da Silva EM
    Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation.
    Sohn YB; Park SW; Kim SH; Cho SY; Ji ST; Kwon EK; Han SJ; Oh SJ; Park YJ; Ko AR; Paik KH; Lee J; Lee DH; Jin DK
    Am J Med Genet A; 2012 May; 158A(5):1158-63. PubMed ID: 22495825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
    Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
    Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
    Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
    Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
    Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy.
    Koseoglu ST; Harmatz P; Turbeville S; Nicely H
    Int Ophthalmol; 2009 Aug; 29(4):267-9. PubMed ID: 18418554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Lampe C; Harmatz PR; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    Mol Genet Metab; 2019 Aug; 127(4):355-360. PubMed ID: 31324526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
    Turner CT; Hopwood JJ; Bond CS; Brooks DA
    Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Illness perception and clinical treatment experiences in patients with M. Maroteaux-Lamy (mucopolysaccharidosis type VI) and a Turkish migration background in Germany.
    Dilger H; Leissner L; Bosanska L; Lampe C; Plöckinger U
    PLoS One; 2013; 8(6):e66804. PubMed ID: 23826140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.
    Krishnagiri C; Ajanahalli RR; Kashyap S; Anegundi R; Boranaik L
    Ann Diagn Pathol; 2013 Feb; 17(1):137-9. PubMed ID: 22056033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional capacity evaluation of patients with mucopolysaccharidosis.
    Guarany NR; Schwartz IV; Guarany FC; Giugliani R
    J Pediatr Rehabil Med; 2012; 5(1):37-46. PubMed ID: 22543891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.